MRNA Stock Recent News

Shares of U.S. biotech companies fell as much as 10% premarket on Monday following reports that a top vaccine official at the U.S. Food and Drug Administration had resigned, fanning worries over slower reviews for breakthrough treatments.

CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian Therapeutic Goods Administration (TGA) has granted approval for mRESVIA® (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to prevent lower respiratory tract disease caused by RSV infection in adults aged 60 years and older.1 mRESVIA's approval marks a significant milestone as it is the first mRNA vaccine in Australia approved for use against a disease beyond COVID-19. "We are pleased to receive regulatory approval for mRESVIA in Australia following the TGA's decision," said Stéphane Bancel, Chief Executive Officer of Moderna.

Valuation always matters in investing. And sometimes you can find stocks that are especially great bargains.

Moderna (MRNA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

It's been nearly five years since Moderna (MRNA -1.60%) emerged as a biotech industry disruptor, with its COVID-19 vaccine playing a landmark role in tackling the global pandemic in late 2020. Despite its generating record sales and profits through 2022, early projections of sustained demand for coronavirus vaccinations failed to materialize, leading to a sharp drop in the business.

Biotech is an area that may offer your portfolio growth today and earnings stability tomorrow. The idea is a biotech stock might soar as investors bet on the company's cutting-edge technology through its development stages -- and the stock could continue to gain after that company moves into the product commercialization stage.

Given the uncertainty around its top-line growth, short-term investors should exercise caution when investing in MRNA stock.

Dublin, March 18, 2025 (GLOBE NEWSWIRE) -- The "mRNA Vaccines Market by Technology Type, Route of Administration, Manufacturing Process, Vaccine Classification, Application Areas, End-User, Distribution Channel - Global Forecast 2025-2030" report has been added to ResearchAndMarkets.com's offering. The mRNA Vaccines Market grew from USD 9.32 billion in 2024 to USD 10.40 billion in 2025. It is expected to continue growing at a CAGR of 11.86%, reaching USD 18.28 billion by 2030. The mRNA vaccine landscape has experienced transformative shifts that underscore the evolution of medical innovation and technological integration. In recent years, unprecedented advances in formulation techniques and delivery systems have redefined the boundaries of vaccine development. Enhanced methods in nucleoside modification, lipid nanoparticle encapsulation, and self-amplifying mRNA platforms mean that vaccines can be deployed more precisely and at greater speeds than previously imagined. These transformat

In the latest trading session, Moderna (MRNA) closed at $34.71, marking a +0.26% move from the previous day.

As we near the five-year anniversary of the COVID-19 pandemic, it's a good time to revisit the drugmaker stock that was top of mind back then. A few years ago, Moderna (MRNA 0.93%) stock soared on the back of the highly successful vaccine it developed in record time.